using the arrow buttons.
by clicking on the page.
the page around when zoomed in by dragging it.
the zoom using the slider when zoomed-in.
by clicking on the zoomed-in page.
by entering text in the search field, and select "This Issue" or "All Issues"
by clicking on thumbnails to select pages, and then press the print button.
displays sections with thumbnails and descriptions.
displays a slider of thumbnails. Click on a page to jump.
allows you to browse the full archive.
about your subscription?
Buddhadharma : Fall 2018
24 BUDDHADHARMA: THE PRACTITIONER'S QUARTERLY From Colorado to California, North Carolina to New York, and beyond, Buddhist practitioners are gathering to experiment with, and discuss the merits of, consciousness-altering substances in the context of their dharma practice. In May, InsightLA and Buddhist Geeks co-hosted “Waking up with Psychedelics” for a sold-out crowd at the Hollywood Forever Cemetery. Trudy Good- man, founder of InsightLA, Buddhist Geek’s Vincent Horn, Washam, and Dr. Charles Grob, Professor of Psychiatry and Pediatrics at the UCLA Medical School, discussed the current confluence of psyche- delics and Buddhist practice on American soil. Ram Dass joined them via livestream. “We know that psychedelics are a valid doorway to dharma prac- tice. It was in the 1960s and still is today. And now, there is a renais- sance of use,” says Mark Koberg, Executive Director of InsightLA. This emergent interest in psychedelics coincides with growing recognition in the wider public sphere of their potential benefits, due in part to a wave of medical research beginning in 2002. In Michael Pollan’s recent book, How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence, he highlights a number of researchers, doctors, and therapists who believe psychedelic ther- apy will soon be “routine and widely available in the form of a novel hybrid of pharmacology and psychotherapy.” Indeed, the medical community has long recognized the thera- peutic potential in psychedelics, but only recently has it been legally allowed to resume clinical trials after they were banned in 1971. Today, multidiscipline teams at Johns Hopkins University School of Medicine, New York University, the Harbor-UCLA Medical Center, the University of New Mexico, Imperial College in London, and the University of Zurich have all have demonstrated that psilocybin (found in magic mushrooms), MDMA (ecstasy), and LSD can have